Catalyst Pharma (NASDAQ: CPRX) CSO’s shares and options canceled in merger
Rhea-AI Filing Summary
Catalyst Pharmaceuticals Chief Strategy Officer Preethi Sundaram reported dispositions tied to the company’s acquisition by Angelini Pharma S.p.A. On July 15, 2026 she disposed of 54,804 shares of common stock at $31.50 per share, and all reported RSUs and stock options were canceled and converted into cash rights, leaving her with no reported common or derivative holdings.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Seller: 54,804 shares
Net Sell
10 txns
Insider
Sundaram Preethi
Role
Chief Strategy Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Options to purchase common stock F3, F5 | 225,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 67,500 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 68,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 143,193 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 137,553 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 106,873 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 6,855 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 11,206 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 32,257 | $0.00 | $0.00 |
| Disposition | Common Stock, par value $0.001 per share F1 | 54,804 | $31.50 | $1.73M |
Holdings After Transaction:
Options to purchase common stock — 0 shares (Direct);
Restricted Stock Units — 0 shares (Direct);
Common Stock, par value $0.001 per share — 0 shares (Direct)
Footnotes (6)
- F1. The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")
- F2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F3. In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option.
- F4. In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU.
- F5. Each Option was fully vested.
- F6. Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger.
Key Figures
Common shares disposed: 54,804 shares
Disposition price per share: $31.50 per share
RSUs canceled (largest tranche): 32,257 units
+3 more
6 metrics
Common shares disposed
54,804 shares
Common Stock disposed on July 15, 2026 in connection with the acquisition
Disposition price per share
$31.50 per share
Price reported for the 54,804 common shares disposed
RSUs canceled (largest tranche)
32,257 units
Restricted Stock Units representing 32,257 shares canceled and converted to cash
Options canceled at $22.77 strike
106,873 options
Options to purchase common stock at $22.77 per share canceled and converted to cash
Options canceled at $5.49 strike
225,000 options
Options to purchase common stock at $5.49 per share canceled and converted to cash
Total disposition transactions
10 transactions
Form 4 reports 1 common stock and 9 derivative disposition entries
Key Terms
Restricted Stock Units, stock option, cash payment, Merger
4 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock option financial
"each reported stock option ("Option") was cancelled and converted into the right"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
cash payment financial
"was cancelled and converted into the right to receive a cash payment"
Merger financial
"In connection with the consummation of the Merger, each reported stock option"
A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Catalyst Pharmaceuticals (CPRX) report for July 15, 2026?
Catalyst Pharmaceuticals reported that Chief Strategy Officer Preethi Sundaram disposed of common shares, RSUs, and stock options on July 15, 2026. These equity awards were canceled and converted into cash rights in connection with the acquisition by Angelini Pharma S.p.A..
What happened to Preethi Sundaram's RSUs in Catalyst Pharmaceuticals (CPRX) after the Angelini merger?
Reported RSUs covering 32,257, 11,206, and 6,855 shares were disposed of. Each RSU, representing one share of common stock, was canceled and converted into a cash payment based on $31.50 per share, less applicable tax withholdings and other authorized deductions.
How were Catalyst Pharmaceuticals (CPRX) stock options treated in the Angelini Pharma acquisition?
Multiple stock option grants, including 106,873 options at a $22.77 exercise price and 225,000 at $5.49, were canceled. Each option was converted into a cash right equal to ($31.50 minus the option’s exercise price) multiplied by the number of option shares.
Does Preethi Sundaram still hold Catalyst Pharmaceuticals (CPRX) equity after the merger?
Following these transactions, the filing shows 0 shares of common stock and 0 reported RSUs or options remaining. All reported common shares, RSUs, and stock options were disposed of or canceled in connection with the Angelini Pharma S.p.A. acquisition.